Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Read More…
Industry, Sector and Symbol
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Phone225-292-2031
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.66 billion
Profitability
Miscellaneous
Employees21,000
Next Earnings Date10/29/2019 (Confirmed)
OptionableOptionable
Amedisys (NASDAQ:AMED) Frequently Asked Questions
What is Amedisys' stock symbol?
Amedisys trades on the NASDAQ under the ticker symbol "AMED."
How were Amedisys' earnings last quarter?
Amedisys Inc (NASDAQ:AMED) posted its quarterly earnings results on Wednesday, July, 31st. The health services provider reported $1.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $0.24. The health services provider had revenue of $492.98 million for the quarter, compared to analysts' expectations of $489.66 million. Amedisys had a net margin of 6.84% and a return on equity of 27.23%. The firm's quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.00 earnings per share. View Amedisys' Earnings History.
When is Amedisys' next earnings date?
How can I listen to Amedisys' earnings call?
Amedisys will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Amedisys issued on next quarter's earnings?
Amedisys updated its FY19 earnings guidance on Wednesday, July, 31st. The company provided earnings per share (EPS) guidance of $4.05-4.12 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.09. The company issued revenue guidance of $1.94-1.98 billion, compared to the consensus revenue estimate of $1.97 billion.
What price target have analysts set for AMED?
10 brokerages have issued twelve-month price targets for Amedisys' shares. Their predictions range from $124.00 to $155.00. On average, they expect Amedisys' share price to reach $140.97 in the next year. This suggests a possible upside of 4.6% from the stock's current price. View Analyst Price Targets for Amedisys.
What is the consensus analysts' recommendation for Amedisys?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amedisys.
Has Amedisys been receiving favorable news coverage?
Press coverage about AMED stock has been trending somewhat positive recently, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amedisys earned a news sentiment score of 0.6 on InfoTrie's scale. They also gave press coverage about the health services provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Amedisys.
Are investors shorting Amedisys?
Amedisys saw a increase in short interest in September. As of September 15th, there was short interest totalling 1,550,000 shares, an increase of 9.2% from the August 15th total of 1,420,000 shares. Based on an average daily volume of 306,500 shares, the days-to-cover ratio is currently 5.1 days. Approximately 4.9% of the shares of the company are sold short. View Amedisys' Current Options Chain.
Who are some of Amedisys' key competitors?
Some companies that are related to Amedisys include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), R1 RCM (RCM), The Providence Service (PRSC), Tivity Health (TVTY), BioScrip (BIOS), Cross Country Healthcare (CCRN), Interpace Diagnostics Group (IDXG) and Bio-Reference Laboratories (BRLI).
What other stocks do shareholders of Amedisys own?
Who are Amedisys' key executives?
Amedisys' management team includes the folowing people:
- Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 58)
- Mr. Scott G. Ginn, Chief Financial Officer (Age 50)
- Mr. Christopher T. Gerard, Chief Operating Officer (Age 52)
- Mr. David L. Kemmerly, Sr. VP of Gov. Affairs & Gen. Counsel (Age 56)
- Ms. Sharon Brunecz, Chief HR Officer (Age 52)
Who are Amedisys' major shareholders?
Amedisys' stock is owned by a number of of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (2.08%), Calamos Advisors LLC (0.13%), Robeco Institutional Asset Management B.V. (0.09%), Envestnet Asset Management Inc. (0.09%), Strs Ohio (0.04%) and Bowling Portfolio Management LLC (0.04%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North, Scott G Ginn and Sharon Brunecz. View Institutional Ownership Trends for Amedisys.
Which institutional investors are selling Amedisys stock?
AMED stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Strs Ohio, Envestnet Asset Management Inc. and Bowling Portfolio Management LLC. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Linda J Hall, Michael Paul North, Scott G Ginn and Sharon Brunecz. View Insider Buying and Selling for Amedisys.
Which institutional investors are buying Amedisys stock?
AMED stock was bought by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, State of Alaska Department of Revenue, Tuttle Tactical Management, Camelot Portfolios LLC, We Are One Seven LLC, Calamos Advisors LLC, State of Michigan Retirement System and Virginia Retirement Systems ET AL. View Insider Buying and Selling for Amedisys.
How do I buy shares of Amedisys?
Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Amedisys' stock price today?
One share of AMED stock can currently be purchased for approximately $134.72.
How big of a company is Amedisys?
Amedisys has a market capitalization of $4.33 billion and generates $1.66 billion in revenue each year. The health services provider earns $119.35 million in net income (profit) each year or $3.63 on an earnings per share basis. Amedisys employs 21,000 workers across the globe.View Additional Information About Amedisys.
What is Amedisys' official website?
How can I contact Amedisys?
Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]
MarketBeat Community Rating for Amedisys (NASDAQ AMED)
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
